PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology
Thymosin α1 (Tα1) is an immunostimulatory peptide for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue...
Main Authors: | Uli Binder, Arne Skerra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/1/124 |
Similar Items
-
Future of anti-VEGF: biosimilars and biobetters
by: Monika Kapur, et al.
Published: (2022-01-01) -
Immunostimulatory photochemotherapeutic nanocapsule for enhanced colon cancer treatment
by: Liu Jie, et al.
Published: (2021-07-01) -
Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide
by: Mijeong Bak, et al.
Published: (2020-04-01) -
NK cell-mediated immunostimulatory effects of ethanol extract of Morinda citrifolia (noni) fruit
by: Haeyeop Kim, et al.
Published: (2022-08-01) -
Self-assembled immunostimulatory nanosphere combined with PD-L1 to enhanced cancer chemoimmunotherapy
by: Haihui Wang, et al.
Published: (2022-11-01)